Next Article in Journal
Recent Advances in Chiral Schiff Base Compounds in 2023
Next Article in Special Issue
Serendipitous Identification of Azine Anticancer Agents Using a Privileged Scaffold Morphing Strategy
Previous Article in Journal
Neuroprotective Effects of Aldehyde-Reducing Composition in an LPS-Induced Neuroinflammation Model of Parkinson’s Disease
Previous Article in Special Issue
Pyrrole-Based Enaminones as Building Blocks for the Synthesis of Indolizines and Pyrrolo[1,2-a]pyrazines Showing Potent Antifungal Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 24
10.3390/molecules28247989
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dimethyl Bisphenolate Ameliorates Carbon Tetrachloride-Induced Liver Injury by Regulating Oxidative Stress-Related Genes

by
Rong Wang
1,2,3,†,
Huanhuan Shen
1,†,
Jiaxiang Zhang
1,
Xiyan Li
1,
Yang Guo
1,
Zhenjun Zhao
3,
Pingyu Wang
4,
Ning Xie
5,
Youjie Li
1,
Guiwu Qu
1,* and
Shuyang Xie
1,2,3,*
1
Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai 264003, China
2
Shandong Laboratory of Advanced Materials and Green Manufacturing (Yantai), Yantai 264000, China
3
College of Life Sciences, Yantai University, Yantai 264005, China
4
Department of Epidemiology, Binzhou Medical University, Yantai 264003, China
5
Department of Breast and Thyroid Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai 264000, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2023, 28(24), 7989; https://doi.org/10.3390/molecules28247989
Submission received: 14 September 2023 / Revised: 7 November 2023 / Accepted: 20 November 2023 / Published: 7 December 2023
(This article belongs to the Special Issue Organic Synthesis and Application of Bioactive Molecules)
Browse Figures
Review Reports Versions Notes

Abstract

:
Liver disease accounts for millions of deaths per year all over the world due to complications from cirrhosis and liver injury. In this study, a novel compound, dimethyl bisphenolate (DMB), was synthesized to investigate its role in ameliorating carbon tetrachloride (CCl4)-induced liver injury through the regulation of oxidative stress-related genes. The structure of DMB was confirmed based on its hydrogen spectrum and mass spectrometry. DMB significantly reduced the high levels of ALT, AST, DBIL, TBIL, ALP, and LDH in a dose-dependent manner in the sera of CCl4-treated rats. The protective effects of DMB on biochemical indicators were similar to those of silymarin. The ROS fluorescence intensity increased in CCl4-treated cells but significantly weakened in DMB-treated cells compared with the controls. DMB significantly increased the content of oxidative stress-related GSH, Nrf2, and GCLC dose-dependently but reduced MDA levels in CCl4-treated cells or the liver tissues of CCl4-treated rats. Moreover, DMB treatment decreased the expression levels of P53 and Bax but increased those of Bcl2. In summary, DMB demonstrated protective effects on CCl4-induced liver injury by regulating oxidative stress-related genes.

1. Introduction

Hepatitis induces liver damage and liver cancer, which, together, cause a million people to die annually. The WHO warns that the diseases induced by viral hepatitis will kill more people than tuberculosis, malaria, and HIV combined by 2040 if the infection trends continue [1]. The Asia–Pacific region accounts for more than 60% of global deaths due to liver diseases. Chronic hepatitis B virus, alcohol consumption, and non-alcoholic fatty liver disease have caused more than half of the deaths attributed to cirrhosis in the region [2]. Many drugs have been deemed to be related to drug-induced liver injury, in which the anti-infective group of drugs is the most frequently implicated [3]. Drug-induced hepatocellular jaundice increases the chance of progressing to death or transplantation for patients [4]. Therefore, there must be a renewed focus on preventing liver injury and reducing the burden of liver diseases.
Drug toxicity can trigger a sterile inflammatory response to induce liver injury, which will cause phagocytes to produce reactive oxygen species (ROS) [5]. ROS-induced liver injury during inflammation is associated with the promotion of mitochondrial dysfunction through intracellular oxidant stress [6]. Khan et al. reported CCl4-induced hepatotoxic liver injuries in mice with the activation of the cytochrome pathway, the formation of ROS, and mitochondrial damage [7]. The generation of ROS can further trigger apoptotic and necrotic cell death.
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is an important transcription factor in neutralizing cellular ROS and restoring redox balance [8]. Nrf2 can govern the expression levels of endogenous antioxidants and ROS-related genes in various electrophilic compounds [9]. Berberine exerts a protective effect against CCl4-induced acute liver injury by effectively regulating the expression of Nrf2-Keap1-related genes and suppressing p53-mediated hepatocyte apoptosis [10]. Various phenolic compounds can cause nuclear factor-κB or Nrf-2 to play important roles in antioxidant responses [11]. Phenolic compounds have anti-inflammatory properties in the treatment of rheumatoid arthritis or inflammatory bowel disease [11].
In a previous study, we found that bisphenolate-ND-309 had antioxidant properties, and it significantly increased the ATP content, attenuated the elevation of malondialdehyde (MDA) levels, and decreased the generation of ROS [12]. This study aimed to identify a new compound that ameliorates liver injury and to study its mechanism of antioxidation. A more active compound (DMB) was synthesized on the basis of bisphenol acid and the previous study. The results demonstrate that it has protective effects on CCl4-induced liver injuries.

2. Results

2.1. Synthesis and Structure of DMB

After the reaction, a total of 10.4 g of yellow powder was obtained through purification via HPLC, with a yield rate of 96.3% and a purity of 99.3%.
The NMR analysis results of DMB is as follows: 1H NMR (600 MHz, d6-DMSO) δ 9.97 (s, 1H, -OH), 9.53 (s, 1H, -OH), 8.84 (s, 1H, -OH), 8.49 (s, 1H, -OH), 7.73 (s, 1H), 7.34 (d, J = 15.9 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 6.56 (d, J = 8.2 Hz, 1H), 6.46 (dd, J = 8.6, 2.2 Hz, 1H), 6.44 (d, J = 2.1 Hz, 1H), 6.28 (d, J = 15.9 Hz, 1H), 3.63 (s, 3H), 3.60 (s, 3H).
13C NMR (151 MHz, d6-DMSO) δ 168.00, 167.40, 148.12, 148.08, 145.40, 143.55, 143.04, 142.26, 126.21, 125.87, 124.24, 123.72, 122.64, 119.01, 117.88, 115.78, 115.76, 115.28, 52.38, 51.66.
The high-resolution mass spectrometry analysis results were as follows: chemical formula: C20H18O8; exact mass: 386.10; molecular weight: 386.36; m/z: 386.10 (100.0%), 387.10 (21.6%), 388.11 (2.2%), 388.10 (1.6%); elemental analysis: C, 62.18; H, 4.70; O, 33.13 (Figure 1A).
The structure of DMB was confirmed on the basis of the above hydrogen spectrum and mass spectrometry data, combined with the structural characteristics of the reactant (bisphenol acid and methanol), as shown in Figure 1B.

2.2. Biochemical and Histological Changes in CCl4-Induced Liver Injury through Oxidative Stress

CCl4 is commonly used in establishing acute liver injury models through the modulation of oxidative imbalance [13,14]. On the basis of the concentration of CCl4 in a previous report [13], five different injection doses, namely, 0, 300, 600, 900, and 1200 μL/kg, were designed to treat SD rats to further determine the appropriate dosage needed in this study. One day after a single injection, the blood of the rats was collected from the apex of the heart, and the sera were tested.
The alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin (DBIL), total bilirubin (TBIL), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) in the sera are the most common liver function indices to estimate liver injury [15,16,17]. When the dose of CCl4 was more than 300 μL/kg, the levels of ALT (Figure 2A) and AST (Figure 2B) in the sera of the rats significantly increased in a dose-dependent manner. The levels of ALT and AST reached the highest under 1200 μL/kg CCl4 treatment. DBIL began to increase under a dose of 600 μL/kg of CCl4 in a dose-dependent manner, and it reached the maximum at 1200 μL/kg CCl4 (Figure 2C). Serum TBIL increased significantly up to 900 μL/kg of CCl4 injections (Figure 2D). ALP and LDH increased significantly with an injection of 600 μL/kg and 1200 μL/kg CCl4, respectively (Figure 2E,F).
Histological changes in the liver structure are important to estimate liver injury [18]. HE staining demonstrated that the liver cell cords of the control rats without an injection of CCl4 were arranged neatly and regularly, with no infiltration of inflammatory factors. A small number of inflammatory cells infiltrated in the liver tissues of the rats after 300 μL/kg CCl4 treatment, but the liver cords remained neat and regular. The liver tissues of the rats treated with 600 and 900 μL/kg CCl4 showed significant vacuolar lesions, pyknosis of the nucleus, and extensive infiltration of inflammatory cells in a dose-dependent manner. After 1200 μL/kg of CCl4 treatment, most cells were on the verge of necrosis, and they demonstrated severe liver damage (Figure 2G). The results indicate that CCl4 dose-dependently has a significant effect on liver injury.
On the basis of the above results, significant biochemical and histological changes were found in the 900 μL/kg CCl4-treated rats. Therefore, 900 μL/kg CCl4 was selected for the following study of the effects of DMB.

2.3. DMB Ameliorated Biochemical and Histological Changes in CCl4-Induced Liver Injury

The SD rats were administered with different concentrations of DMB (low dose, 15 mg/Kg; medium dose, 30 mg/Kg; and high dose, 45 mg/Kg) via gastric gavage for 1 week to investigate the protective roles of DMB in liver injury. The rats were then treated with 900 μL/Kg CCl4. The results demonstrate that DMB significantly reduced the high levels of ALT (Figure 3A) and AST (Figure 3B) in a dose-dependent manner in the sera of the CCl4-induced liver injury rats. DMB also reduced the upregulating trends of DBIL (Figure 3C), TBIL (Figure 3D), ALP (Figure 3E), and LDH (Figure 3F) caused by CCl4. The protective effects of DMB on the biochemical indicators were similar to or better than those of 43.75 mg/Kg silymarin (clinical drug used as positive control treatment, Figure 3A–F).
HE staining further supported the notion that the low, medium, and high doses of DMB ameliorated the histological liver injury induced by CCl4, similar to silymarin (Figure 3G). These results indicate that DMB can effectively reduce the indicators of CCl4-induced liver injury.

2.4. DMB Increased Oxidative Stress-Related Nrf2/GCLC in CCl4-Induced Liver Injury of Rats

Emerging evidence supports a link between oxidative stress and mitochondrial dysfunction in CCl4-induced liver injury [13,19]. The above-mentioned results show that DMB ameliorated CCl4-induced liver injury. The possible binding proteins were predicted using SEA and SuperPred to further investigate the molecular mechanism of DMB in liver injury, and the results demonstrate that Nrf2 is a target of DMB (Supplemental Tables S1 and S2). Moreover, arginine (ARG) at position 322, valine (VAL) at position 420, glycine (GLY) at position 511, and VAL at position 512 in NRF2 can bind to DMB through hydrogen bonds (Figure 4A).
These results indicate that Nrf2 is a target of DMB. Nrf2 functions as a ubiquitous and evolutionarily conserved protein to counteract oxidative stress [20] and, thus, participates in the pathological process of liver injury [21]. Therefore, the roles of Nrf2 in liver injury were investigated in this study. Nrf2, as a controller of enzymes, is important for producing glutathione (GSH) and MDA [22]. The levels of GSH and MDA were detected to study the roles of DMB-related Nrf2 in CCl4-induced liver injury. The results show that CCl4 reduced the content of GSH in the liver tissues compared with the control. DMB treatment significantly increased the content of GSH in the liver tissues of the CCl4-treated rats (Figure 4B). Meanwhile, CCl4 significantly increased the content of MDA in the liver tissues, and this content was significantly reduced after DMB treatment. As the concentration of DMB increased, the content of MDA gradually decreased (Figure 4C). Similar results of GSH and MDA were found in the silymarin-treated rats (Figure 4B,C). Compared with the normal controls, the expression levels of Nrf2 and GCLC decreased in the liver tissues of the CCl4-treated rats, and DMB treatment increased these levels in a dose-dependent manner (Figure 4D–F).
Nrf2 can inhibit p53 expression in the liver and cultured hepatocytes [23]. ROS, which is generated during oxidative stress, can enhance p53 expression and activate pro-oxidant genes to result in p53-dependent apoptosis [24]. The expression levels of P53, Bax, and Bcl2 in the liver tissues were detected. The results show that the expression of P53 and Bax increased in the liver tissues of CCl4-induced models, whereas that of Bcl2 decreased compared with the controls. Meanwhile, DMB treatment decreased the expression levels of p53 and Bax but increased those of Bcl2, and the changes in p53, Bax, or Bcl2 induced by DMB were similar to the effects of silymarin on the expression of these genes (Figure 4D,G,H). The results further indicate that the molecular mechanism of DMB in protecting against liver injury is related to the regulation of the expression levels of P53, Bax, and Bcl2.

2.5. DMB Ameliorated Oxidative Stress Induced by CCl4 to HepG2 and MHCC-97H Cells

The above-mentioned results demonstrate that DMB has a protective effect on liver injury in rats. The roles of DMB in ameliorating the injury induced by CCl4 in vitro were further investigated in HepG2 and MHCC-97H cells. First, 10 different volume concentrations were set. Second, the half maximal inhibitory concentration (IC50) of CCl4 on HepG2 and MHCC-97H cells was determined through CCK-8 experiments. The IC50 values in HepG2 and MHCC-97H cells were determined to be 0.3% (Figure 5A) and 0.25% (Figure 5B), respectively.
A 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) experiment further indicated that DMB effectively protected the cells from the injury induced by CCl4 in vitro. When the concentration of DMB reached 20 and 30 μg/mL, the injury induced by CCl4 to the cells was almost fully reversed, and the cell activity was similar to that after control treatment (Figure 5C,D). Therefore, 20 μg/mL was selected as the experimental concentration of DMB in the following experiments.
Then, the MDA and GSH levels were detected to study the roles of DMB in reversing CCl4-induced cell injury in vitro. The results show that the increase in MDA levels or the decrease in GSH levels induced by CCl4 was reversed in DMB-treated HepG2 or MHCC-97H cells compared with that in the controls (Figure 5E,F), similar to the results of the in vivo study.
Oxidative stress is a phenomenon of ROS accumulation in cells [25]. An increase in GSH can reduce the contents of ROS and MDA to ameliorate oxidative stress [26]. The results of the present study show that the ROS fluorescence intensity significantly increased in CCl4-treated HepG2 or MHCC-97H cells and significantly weakened in DMB-treated cells compared with the controls (Figure 5G,H). The results demonstrate that DMB has antioxidant effects on reducing MDA and ROS by increasing GSH levels in vitro.
Western blot and immunofluorescence analyses further demonstrated that CCl4 treatment reduced the expression levels of Nrf2 and GCLC in HepG2 or MHCC-97H cells compared with those in the controls (Figure 6A–D). Nevertheless, DMB ameliorated the roles of CCl4-reduced Nrf2 and GCLC in cells (Figure 6A,B), indicating that the antioxidant effects of DMB are related to the regulation of Nrf2 and GCLC expression levels.

2.6. DMB Reversed Cell Apoptosis Induced by CCl4

The results demonstrate that CCl4 treatment significantly increased the number of apoptotic cells compared with the control treatment. DMB ameliorated the effects of CCl4-induced cell apoptosis in HepG2 and MHCC-97H cells (Figure 7A,B). Western blot further revealed that CCl4 treatment increased p53 and Bax expression and decreased Bcl-2 levels, whereas DMB reversed these changes (Figure 7C,D). The results further support the notion that the anti-apoptotic role of DMB is related to the regulation of the expression of p53-related genes.
The above-mentioned results indicate that DMB ameliorates the roles of CCl4-induced liver injury by regulating Nrf2-related genes. Next, the cytotoxicity of DMB in vitro and in vivo was assessed. The results show that 10, 20, 30, 60, and 100 μg/mL DMB treatments were not cytotoxic to MHCC-97H and 293T cells (Supplemental Figure S1). In the in vitro study, the treatment of 45 mg/kg DMB did not induce significant changes in the liver tissues (Supplemental Figure S2) according to a histological analysis. The results support the notion that DMB does not significantly induce cytotoxicity in vitro and in vivo.

3. Discussion

Liver disease, which is a significant clinical problem, accounts for millions of deaths per year all over the world due to complications from cirrhosis and liver injury [27]. Thus, new treatment for liver injury is urgently needed. A biochemical analysis demonstrated that lachnum polysaccharide treatment improved the antioxidant status (GSH and MDA) and showed protection against liver injury [28]. Salvia miltiorrhiza polysaccharides demonstrated a good protective effect on liver damage by increasing the content of GSH and decreasing the levels of ALT, AST, and MDA [29]. In this study, a new compound (DMB) was synthesized, and the results show that DMB ameliorates the roles of CCl4-induced liver injury by increasing Nrf2, GCLC, and GSH levels and decreasing ROS levels (Figure 8).
CCl4 is commonly used to induce liver injury in animal models. An intraperitoneal injection of CCl4 can result in liver inflammation and oxidative stress through the downregulation of superoxide dismutase and GSH [30]. CCl4 increased plasma ALT and AST activities and induced hepatic fibrosis formation by decreasing α-SMA and collagen proteins [31]. We found that significant changes in ALT, AST, DBIL, TBIL, and liver structures occurred in the CCl4-treated rats; these results are supported by those of Ebaid [32], who showed that CCl4 significantly upregulated the levels of lipid peroxidation (MDA), cholesterol, LDL, and bilirubin but significantly suppressed the activity of GSH.
GSH, which is a ubiquitous intracellular peptide, plays important roles in detoxification and antioxidant defense [33]. GSH synthesis is regulated by the activity of the rate-limiting enzyme glutamate cysteine ligase (GCL), which is composed of a catalytic (GCLC) and a modifier subunit [34]. Oxidative stress can induce the expression of GSH synthetic enzymes to further affect ROS levels. The Nrf2 pathway, a powerful sensor for the cellular redox state, is activated directly by oxidative stress, and it can increase GCL levels and the content of GSH [35]. Chen et al. showed that the nuclear translocation of Nrf2 increased in 5-caffeoylquinic acid (5-CQA)-treated HepG2 cells. 5-CQA can significantly increase the Nrf2-antioxidant response element activity, and Nrf2 inhibition completely antagonized the ability of 5-CQA to induce GCL expression [36]. Here, we found that the new compound DMB significantly increased the content of GSH, Nrf2, and GCLC in the liver tissues of the rats with CCL4-induced liver injury. Considering the roles of ROS in inflammation [25], our results indicate that DMB may ameliorate liver inflammation by regulating GSH, Nrf2, and GCLC to reduce ROS.
Nrf2 can affect the expression of p53 in the liver and cultured hepatocytes [23]. Moreover, the livers of the CCl4-treated mice exhibited a marked increase in the expression of P53 and Bax and a downregulation in Bcl2 expression [37]. The results in this study show similar changes in the p53-related genes of CCl4-induced liver injury tissues. Western blot showed that the p53 and Bax expression levels increased and that the Nrf2 and Bcl2 levels decreased in CCl4-induced liver cells or tissues. Meanwhile, DMB treatment decreased the expressions of P53 and Bax but increased those of Nrf2 and Bcl2 compared with CCl4-treated cells or tissues.
Silymarin is a hepatoprotective agent widely used for the therapy of liver injury [38]. It acts as an antioxidant that can reduce free radical production and lipid peroxidation, and it has antifibrotic activity. Considering its protective roles in liver injury, silymarin was used to ameliorate liver injury caused by CCl4, acetaminophen, phenylhydrazine, and alcohol [39]. Hussein et al. showed that silymarin protected against liver injury via antioxidant and anti-apoptotic activities through the regulation of Keap1-Nrf2/HO-1 expression [40]. Considering its roles in protecting liver injury through antioxidant and anti-apoptotic activities, silymarin was used as a positive control in this study. Interestingly, the results indicate that the protective effects of DMB on ameliorating liver injury were similar to or better than those of silymarin. Therefore, DMB has potential application or combination with silymarin in the protection against liver injury.
To sum up, our results show that CCl4 can induce liver injury through two aspects. It increases oxidative stress by suppressing the expression of Nrf2 and GCLC to reduce GSH levels. CCl4 increases ROS levels to further induce cell apoptosis by regulating p53-related genes. The results show that DMB ameliorates the roles of CCl4-induced liver injury. The possible mechanism may be related to the increase in Nrf2, GCLC, and GSH levels and the decrease in ROS. DMB may be applied in clinical practice for liver injury in the future. However, the detailed regulating mechanism and the cytotoxicity of DMB, such as its side effects and concentration in vivo, must be further investigated.

4. Materials and Methods

4.1. DMB Synthesis

Bisphenol acid (10.0 g, Yantai Institute of Chemical Industry, Yantai, China) was dissolved in 100 mL methanol, and then hydrochloric acid was added to react for 4 h. A total of 10.4 g yellow powder was obtained after reducing the pressure at 50 °C and drying at vacuum. The yellow powder was mixed with silica gel at a mass ratio of 1:1 and eluted with a mixture gradient of chloroform and methanol. Toluene-trichloromethane-ethyl-acetate-methanol formic acid (ratio, 2:3:4:0.5:0.2) was detected, and the highest content of the eluted portion was collected to dry at 50 °C. Then, HPLC was used to analyze the DMB as follows: C18 reverse-phase chromatographic column, detection wavelength of 286 nm, and mobile phase of 2% formic acid (A)–acetonitrile (B). The gradient elution procedure was as follows: 0−15 min, 10% B to 100% B; 15−20 min, 100% B; 20−25 min, 100% B to 10% B; 25−30 min, 10% B.

4.2. DMB Structure Analysis

The DMB structure was analyzed using a nuclear magnetic resonance instrument (Advance III 50, Bruker, Billerica, MA, USA) and mass spectrometry (Q-Exactive, ThermoFisher, Norristown, PA, USA). The conditions of mass spectrometry were as follows: The ion source was HESI, with negative ion detection mode; the sheath gas flow rate was 35 arb. The auxiliary gas volume flow rate was 10 arb; the spray voltage was 2.80 kV. The temperature of the ion transfer tube and auxiliary gas was 325 °C and 350 °C, respectively. The scanning mode was as follows: Full MS/dd MS2; the resolution of Full MS was 70,000; the resolution of dd-MS2 was 17,500; and the scanning range was 100 to 1000 m/z.

4.3. Rat Model

SD rats (Jinan Pengyue Experimental Animal Breeding Co., Ltd., Jinan, China) were randomly divided by a “blinded” investigator into a normal control group; a model group; a silymarin group (43.75 mg/kg based on clinical medication conversion); and DMB low- (15 mg/kg), medium- (30 mg/kg), and high-dose groups (45 mg/kg), with 6 rats in each group. The drugs were administered at appropriate concentrations by using a 1% sodium carboxymethyl cellulose solution as the solvent. Each medication group was administered with a volume of 1 mL/300 g via gavage, once a day for 7 consecutive days. The normal control rats were given an equal volume of 1% carboxymethyl cellulose sodium solution via gavage. Two hours after the end of the previous administration, the model group and each drug group were given a one-time intraperitoneal injection of 900 μL/kg CCl4 (Fuyu Fine Chemical Co., Ltd., Tianjin, China) solution. The normal controls were intraperitoneally injected with an equal volume of olive oil. All animal experiments were approved by the Animal Ethics Committee of Binzhou Medical University (No. 2021-06-03).

4.4. Biochemical Indicator Analysis

Twenty-four hours after the intraperitoneal injection of the CCl4 solution into the rats, 2% pentobarbital sodium was administered intraperitoneally as anesthesia. Blood was taken from the rat’s apex by using a syringe and placed at room temperature for 2 h. The ALT, AST, DBIL, TBIL, ALP, and LDH levels in the sera were analyzed by using an Advia2400 biochemical analyzer (Siemens, Munich, Germany). The detailed detection of these indicators is shown in the supplemental methods.

4.5. Pathological Changes in Liver Tissues

The liver tissues were separated and fixed in 4% paraformaldehyde solution (BL539A, biosharp, Shanghai, China) for 24 h. The tissues were dehydrated, embedded in paraffin, sliced to a thickness of 4 μm, and stained with HE. The pathological changes in the rat liver tissues were observed under a microscope (DM6000B, Leica, Dresden, Germany) by a liver pathologist.

4.6. Detection of MDA and GSH Content

The frozen liver tissues were thawed at room temperature. Following the instructions of the corresponding MDA reagent kit (S0131S, Beyotime Biotechnology, Shanghai, China), 0.1 mL samples were added into each vial with 0.2 mL MDA detection working solution. The mixture was mixed and incubated in boiling water. Then, it was cooled and centrifuged at 1000× g for 10 min at room temperature. ELISA was used to determine the contents of MDA in the liver tissues.
GSH was analyzed using a GSH kit in accordance with the manufacturer’s instructions (S0053, Beyotime Biotechnology, Shanghai, China). Briefly, reactions, including samples, protein removal reagent M solution, and total glutathione assay working solution, were prepared in 96-well plates and incubated at room temperature for 5 min. Then, 50 µL of 0.5 mg/mL NADPH solution was added to each well, mixed, and detected using ELISA.

4.7. Prediction of DMB-Related Proteins

The structure of DMB (SMILES) was identified using SwissTargetPrediction (http://swisstargetprediction.ch/ (accessed on 16 October 2022)) to predict DMB-related proteins. Based on the structure of DMB, the possible binding proteins were predicted using SEA (http://sea.bkslab.org/ (accessed on 16 October 2022)) and SuperPred (https://prediction.charite.de/index.php?site=chemdoodle_search_target (accessed on 16 October 2022)).
The structure of the Nrf2 protein was downloaded through RCSB PDB, and CHem 3D 20.0 software (CJMarketing, Suzhou, China) was used to convert the secondary structure of DMB into a 3D structure for optimization. PyMOL 2.6 software (DeLano Scientific LLC, USA) was used to remove water and residue from Nrf2, and AutoDockTools 4.26 software (Scripps Research Institute, USA) was used for molecular simulation docking.

4.8. Cell Culture

HepG2 and MHCC-97H cells were obtained from the Shanghai Institute of Cell Biology, China. They were cultured in a DEME medium (high glucose; Hyclone, Logan, UT, USA) supplemented with 10% FBS and 5% CO2 at 37 °C.
After the HepG2 and MHCC-97H cells (5 × 103 cells each well) were inoculated on 96-well plates for 24 h, different volume concentrations of CCl4 (from 0.05% to 0.4%) were added for another 24 h. After the culture medium was removed, CCK-8 (BS350C, Biosharp, China) was added to the cells and incubated at 37 °C for 2 h. The optical density (OD) was measured at 450 nm by using an ELISA reader (Multiskan FC, Thermo Fisher Scientific, Waltham, MA, USA) to calculate IC50.

4.9. MTT Assay

An MTT assay was used to analyze cell proliferation according to previous reports [41,42]. In brief, cells (1 × 104) were cultured in each well of the 96-well plates. At 4 h before the end of incubation, 10 μL MTT (Sigma, St Louis, MO, USA, 5 mg/mL) was added to each well. After the supernatant was removed, 100 μL DMSO (Sigma) was added, and the OD was measured using an ELISA reader (Multiskan FC, Thermo Fisher Scientific).

4.10. ROS Content Analysis

The cells (5 × 106) were inoculated in a six-well plate for 24 h, and the CCl4-treated cells were further incubated with or without DMB. They were then collected and stained using 10 μM DCFH-DA (S0033S, Beyotime Biotechnology, Shanghai, China) at 37 °C for 20 min. The fluorescence intensity was analyzed using a microscope (LEICA TCS SPE, Leica, Dresden, Germany).

4.11. Cell Apoptosis

Apoptotic cells were analyzed using an Annexin V-FITC/PI kit (KeyGEN Biotech, Co., Ltd., Nanjing, China). The cells were collected and resuspended in PBS gently. Then, they were centrifuged and resuspended in 195 μL Annexin V-FITC binding buffer. Annexin V-FITC (5 µL) was added, and 10 µL propidium iodide was mixed gently. The mixture was incubated in the dark for 10–20 min and examined immediately using flow cytometry (Beckman Coulter, Lane Cove West, NSW, Australia) as previously described [42,43].

4.12. Western Blot

The total proteins were extracted from the liver tissues or cells as previously described [42,44]; separated with 10% SDS-PAGE; and transferred to PVDF membranes, which were then blocked with 5% milk and incubated with primary and goat anti-rabbit IgG (H+L) secondary antibodies (1:6000, MB001, Bioworld, Minneapolis, MN, USA) separately. The membranes were analyzed using enhanced chemiluminescence substrates (P0018M, BeyoECL Plus, Beyotime, Nantong, China). The antibodies were as follows: rabbit anti-human or rat Nrf2 (1:2000, BS6286, Bioworld Technology, Ltd., Minneapolis, MN, USA), rabbit anti-human or rat glutamate cysteine ligase catalytic (GCLC, 1:6000, 12601-1-AP, Proteintech, Rosemont, IL, USA), rabbit anti-human or rat P53 (1:2000, 21891-1-AP, Proteintech), rabbit anti-human or rat Bax (1:1000, BS6420, Bioworld), rabbit anti-human or rat Bcl2 (1:1000, BS70205, Bioworld), and rabbit anti-human or rat GAPDH (1:3000, AP0063, Bioworld).

4.13. Immunofluorescence Analysis

Cell slides were washed with PBS and fixed at room temperature with 4% paraformaldehyde (BL539A, Biosharp, China) for 2 h. They were then broken using 0.2% TritonX-100 at room temperature for 15 min and sealed with a sealing solution at room temperature for 1 h. The first antibody rabbit anti-human Nrf2 (1:100, Bioworld Technology, Ltd., MN, USA) was incubated overnight, and the second antibody was incubated at 37 °C in the dark for 2 h and then incubated with DAPI (C1006, Beyotime Biotechnology, Shanghai, China) for 5 min. The fluorescence was analyzed using a microscope (DM6000 B, Leica, Dresden, Germany) as previously described [44].

4.14. Statistics

SPSS 22.0 software was used to analyze statistical significance (IBM Corp., Armonk, NY, USA). The median (interquartile range) is presented for abnormally distributed data, and multiple groups were compared using the Kruskal–Wallis H test. Normally distributed data are presented as mean ± SD. Multiple groups were compared using ANOVA. Tukey’s test was used for multiple comparisons. p < 0.05 indicated a statistically significant difference.

5. Conclusions

The novel compound DMB was synthesized, and it demonstrated similar protective effects on CCl4-induced liver injury to silymarin. The protective mechanism of DMB in liver injury is related to the regulation of the expression of Nrf2-related genes. This study shows the potential application of DMB to liver injury.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28247989/s1.

Author Contributions

S.X. conceived the study; G.Q., Y.L. and S.X. designed the experiments; R.W., J.Z., H.S. and X.L. performed the CCK8, MTT, immunofluorescence staining, and FACS experiments; R.W., Z.Z., J.Z. and Y.G. performed the RT-PCR and immunoblotting experiments; P.W. and Z.Z. analyzed the data; N.X. performed the detection of biochemical indicators; S.X., G.Q. and N.X. prepared the figures; Y.L., G.Q. and S.X. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The present study was supported by the Natural Science Foundation of Shandong province (No. ZR2022LSW002, ZR2020KH015), the Education Department of Shandong Province (2021KJK005), and the Science Fund of Shandong Laboratory of Advanced Materials and Green Manufacturing (Yantai) (AMGM2023F16).

Institutional Review Board Statement

This study was approved by the Animal Ethics Committee of Binzhou Medical University. The number is No. 2021-06-03.

Informed Consent Statement

Not applicable.

Data Availability Statement

All of the data are contained within the article and the Supplementary Materials.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

DMB, dimethyl bisphenolate; CCl4,carbon tetrachloride; ROS, reactive oxygen species; Nrf2, nuclear factor erythroid 2-related factor 2; MDA, malondialdehyde; GCLC, glutamate cysteine ligase catalytic; GSH, glutathione; OD, optical density; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ALT, alanine aminotransfetase; AST, aspartate aminotransfetase; DBIL, direct bilirubin; TBIL, total bilirubin; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; ARG, arginine; VAL, valine; GLY, glycine; IC50, half maximal inhibitory concentration; GCL, glutamate cysteine ligase.

References

  1. World Health Organization (WHO). WHO Launches “One Life, One Liver” Campaign on World Hepatitis Day. World Health Organization. 2023. Available online: https://www.who.int/news/item/28-07-2023-who-launches--one-life--one-liver--campaign-on-world-hepatitis-day (accessed on 28 July 2023).
  2. Sarin, S.K.; Kumar, M.; Eslam, M.; George, J.; Al Mahtab, M.; Akbar, S.M.F.; Jia, J.D.; Tian, Q.J.; Aggarwal, R.; Muljono, D.H.; et al. Liver diseases in the Asia-Pacific region: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2020, 5, 167–228. [Google Scholar] [CrossRef] [PubMed]
  3. Andrade, R.J.; Lucena, M.I.; Fernández, M.C.; Pelaez, G.; Pachkoria, K.; García-Ruiz, E.; García-Muñoz, B.; González-Grande, R.; Pizarro, A.; Durán, J.A.; et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129, 512–521. [Google Scholar] [CrossRef]
  4. Katarey, D.; Verma, S. Drug-induced liver injury. Clin. Med. 2016, 16 (Suppl. S6), s104–s109. [Google Scholar] [CrossRef]
  5. Jaeschke, H. Reactive oxygen and mechanisms of inflammatory liver injury. J. Gastroenterol. Hepatol. 2000, 15, 718–724. [Google Scholar] [CrossRef]
  6. Bardallo, R.G.; Panisello-Roselló, A.; Sanchez-Nuno, S.; Alva, N.; Roselló-Catafau, J.; Carbonell, T. Nrf2 and oxidative stress in liver ischemia/reperfusion injury. FEBS J. 2022, 289, 5463–5479. [Google Scholar] [CrossRef]
  7. Khan, H.A.; Ahmad, M.Z.; Khan, J.A.; Arshad, M.I. Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance. Hepatobiliary Pancreat. Dis. Int. HBPD INT 2017, 16, s1499–s3872. [Google Scholar] [CrossRef]
  8. Jobe, M.C.; Mthiyane, D.M.N.; Dludla, P.V.; Mazibuko-Mbeje, S.E.; Onwudiwe, D.C.; Mwanza, M. Pathological Role of Oxidative Stress in Aflatoxin-Induced Toxicity in Different Experimental Models and Protective Effect of Phytochemicals: A Review. Molecules 2023, 28, 5369. [Google Scholar] [CrossRef]
  9. Kasai, S.; Shimizu, S.; Tatara, Y.; Mimura, J.; Itoh, K. Regulation of Nrf2 by Mitochondrial Reactive Oxygen Species in Physiology and Pathology. Biomolecules 2020, 10, 320. [Google Scholar] [CrossRef]
  10. Han, C.Y.; Sun, T.T.; Xv, G.P.; Wang, S.S.; Gu, J.G.; Liu, C.Y. Berberine ameliorates CCl4-induced liver injury in rats through regulation of the Nrf2-Keap1-ARE and p53 signaling pathways. Mol. Med. Rep. 2019, 20, 3095–3102. [Google Scholar] [CrossRef] [PubMed]
  11. Rahman, M.M.; Rahaman, M.S.; Islam, M.R.; Rahman, F.; Mithi, F.M.; Alqahtani, T.; Almikhlafi, M.A.; Alghamdi, S.Q.; Al-ruwaili, A.S.; Hossain, M.S.; et al. Role of Phenolic Compounds in Human Disease: Current Knowledge and Future Pro-spects. Molecules 2021, 27, 233. [Google Scholar] [CrossRef] [PubMed]
  12. Tian, J.; Li, G.; Liu, Z.; Zhang, S.; Qu, G.; Jiang, W.; Fu, F. ND-309, a novel compound, ameliorates cerebral infarction in rats by antioxidant action. Neurosci. Lett. 2008, 442, 279–283. [Google Scholar] [CrossRef] [PubMed]
  13. Di Paola, R.; Modafferi, S.; Siracusa, R.; Cordaro, M.; D’Amico, R.; Ontario, M.L.; Interdonato, L.; Salinaro, A.T.; Fusco, R.; Impellizzeri, D.; et al. S-Acetyl-Glutathione Attenuates Carbon Tetrachloride-Induced Liver Injury by Modulating Oxidative Imbalance and Inflammation. Int. J. Mol. Sci. 2022, 23, 4429. [Google Scholar] [CrossRef]
  14. Wang, B.; Cui, S.; Mao, B.; Zhang, Q.; Tian, F.; Zhao, J.; Tang, X.; Chen, W. Cyanidin Alleviated CCl(4)-Induced Acute Liver Injury by Regulating the Nrf2 and NF-κB Signaling Pathways. Antioxidants 2022, 11, 2383. [Google Scholar] [CrossRef]
  15. Yan, J.; Xie, G.; Liang, C.; Hu, Y.; Zhao, A.; Huang, F.; Hu, P.; Liu, P.; Jia, W.; Wang, X. Herbal medicine Yinchenhaotang protects against α-naphthylisothiocyanate-induced cholestasis in rats. Sci. Rep. 2017, 7, 4211. [Google Scholar] [CrossRef]
  16. Liu, S.; Wu, J.; Chen, P.; Mohammed, S.A.D.; Zhang, J.; Liu, S. TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis. BioMed Res. Int. 2022, 2022, 4949148. [Google Scholar] [CrossRef]
  17. Mu, Y.; Sun, J.; Li, Z.; Zhang, W.; Liu, Z.; Li, C.; Peng, C.; Cui, G.; Shao, H.; Du, Z. Activation of pyroptosis and ferroptosis is involved in the hepatotoxicity induced by polystyrene microplastics in mice. Chemosphere 2022, 291, 132944. [Google Scholar] [CrossRef]
  18. Mohamed, D.A.; Mohamed, N.M.; Abdelrahaman, S. Histological and Biochemical Changes in Adult Male Rat Liver after Spinal Cord Injury with Evaluation of the Role of Granulocyte-Colony Stimulating Factor. Ultrastruct. Pathol. 2020, 44, 395–411. [Google Scholar] [CrossRef] [PubMed]
  19. Bak, J.; Je, N.K.; Chung, H.Y.; Yokozawa, T.; Yoon, S.; Moon, J.O. Oligonol Ameliorates CCl₄-Induced Liver Injury in Rats via the NF-Kappa B and MAPK Signaling Pathways. Oxidative Med. Cell. Longev. 2016, 2016, 3935841. [Google Scholar] [CrossRef] [PubMed]
  20. Bellezza, I.; Giambanco, I.; Minelli, A.; Donato, R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim. Et Biophys. Acta. Mol. Cell Res. 2018, 1865, 721–733. [Google Scholar] [CrossRef]
  21. Ding, X.; Jian, T.; Wu, Y.; Zuo, Y.; Li, J.; Lv, H.; Ma, L.; Ren, B.; Zhao, L.; Li, W.; et al. Ellagic acid a-meliorates oxidative stress and insulin resistance in high glucose-treated HepG2 cells via miR-223/ke-ap1-Nrf2 pathway. Biomed. Pharmacother. Biomed. Pharmacother. 2019, 110, 85–94. [Google Scholar] [CrossRef]
  22. Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931–947. [Google Scholar] [CrossRef] [PubMed]
  23. Lu, C.; Xu, W.; Zhang, F.; Shao, J.; Zheng, S. Nrf2 Knockdown Disrupts the Protective Effect of Curcumin on Alcohol-Induced Hepatocyte Necroptosis. Mol. Pharm. 2016, 13, 4043–4053. [Google Scholar] [CrossRef] [PubMed]
  24. Chen, W.; Jiang, T.; Wang, H.; Tao, S.; Lau, A.; Fang, D.; Zhang, D.D. Does Nrf2 contribute to p53-mediated control of cell survival and death? Antioxid. Redox Signal. 2012, 17, 1670–1675. [Google Scholar] [CrossRef]
  25. Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative Stress: Harms and Benefits for Human Health. Oxidative Med. Cell. Longev. 2017, 2017, 8416763. [Google Scholar] [CrossRef]
  26. Tai, F.; Wang, S.; Liang, B.; Li, Y.; Wu, J.; Fan, C.; Hu, X.; Wang, H.; He, R.; Wang, W. Quaternary ammonium iminofullerenes improve root growth of oxidative-stress maize through ASA-GSH cycle modulating redox homeostasis of roots and ROS-mediated root-hair elongation. J. Nanobiotechnol. 2022, 20, 15. [Google Scholar] [CrossRef]
  27. Asrani, S.K.; Devarbhavi, H.; Eaton, J.; Kamath, P.S. Burden of liver diseases in the world. J. Hepatol. 2019, 70, 151–171. [Google Scholar] [CrossRef]
  28. Hou, G.; Surhio, M.M.; Ye, H.; Gao, X.; Ye, Z.; Li, J.; Ye, M. Protective effects of a Lachnum polysaccharide against liver and kidney injury induced by lead exposure in mice. Int. J. Biol. Macromol. 2019, 124, 716–723. [Google Scholar] [CrossRef]
  29. Han, C.; Wei, Y.; Wang, X.; Ba, C.; Shi, W. Protective effect of Salvia miltiorrhiza polysaccharides on liver injury in chickens. Poult. Sci. 2019, 98, 3496–3503. [Google Scholar] [CrossRef]
  30. Ali, H.; Jahan, A.; Samrana, S.; Ali, A.; Ali, S.; Kabir, N.; Ali, A.; Ullah, R.; Mothana, R.A.; Murtaza, B.N.; et al. Hepatoprotective Potential of Pomegranate in Curbing the Incidence of Acute Liver Injury by Alleviating Oxidative Stress and Inflammatory Response. Front. Pharmacol. 2021, 12, 694607. [Google Scholar] [CrossRef]
  31. Wang, Y.; Deng, X.; Liu, Y.; Wang, Y.; Luo, X.; Zhao, T.; Wang, Z.; Cheng, G. Protective effect of Anneslea fragrans ethanolic extract against CCl(4)-induced liver injury by inhibiting inflammatory response, oxidative stress and apoptosis. Food Chem. Toxicol. Int. J. Public Br. Ind. Biol. Res. Assoc. 2023, 175, 113752. [Google Scholar] [CrossRef] [PubMed]
  32. Ebaid, H.; Bashandy, S.A.; Alhazza, I.M.; Rady, A.; El-Shehry, S. Folic acid and melatonin ameliorate carbon tetrachloride-induced hepatic injury, oxidative stress and inflammation in rats. Nutr. Metab. 2013, 10, 20. [Google Scholar] [CrossRef]
  33. Ribas, V.; García-Ruiz, C.; Fernández-Checa, J.C. Glutathione and mitochondria. Front. Pharmacol. 2014, 5, 151. [Google Scholar] [CrossRef]
  34. Lu, S.C. Regulation of glutathione synthesis. Mol. Asp. Med. 2009, 30, 42–59. [Google Scholar] [CrossRef]
  35. Yang, J.H.; Shin, B.Y.; Han, J.Y.; Kim, M.G.; Wi, J.E.; Kim, Y.W.; Cho, I.J.; Kim, S.C.; Shin, S.M.; Ki, S.H. Isorhamnetin protects against oxidative stress by activating Nrf2 and inducing the expression of its target genes. Toxicol. Appl. Pharmacol. 2014, 274, 293–301. [Google Scholar] [CrossRef] [PubMed]
  36. Chen, X.; Yang, J.H.; Cho, S.S.; Kim, J.H.; Xu, J.; Seo, K.; Ki, S.H. 5-Caffeoylquinic acid ameliorates oxidative stress-mediated cell death via Nrf2 activation in hepatocytes. Pharm. Biol. 2020, 58, 999–1005. [Google Scholar] [CrossRef] [PubMed]
  37. Badr, G.; Sayed, E.A.; Waly, H.; Hassan, K.A.; Mahmoud, M.H.; Selamoglu, Z. The Therapeutic Mechanisms of Propolis Against CCl(4) -Mediated Liver Injury by Mediating Apoptosis of Activated Hepatic Stellate Cells and Improving the Hepatic Architecture through PI3K/AKT/mTOR, TGF-β/Smad2, Bcl2/BAX/P53 and iNOS Signaling Pathways. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2019, 53, 301–322. [Google Scholar] [CrossRef]
  38. Papackova, Z.; Heczkova, M.; Dankova, H.; Sticova, E.; Lodererova, A.; Bartonova, L.; Poruba, M.; Cahova, M. Silymarin prevents acetaminophen-induced hepatotoxicity in mice. PLoS ONE 2018, 13, e0191353. [Google Scholar] [CrossRef] [PubMed]
  39. Abenavoli, L.; Capasso, R.; Milic, N.; Capasso, F. Milk thistle in liver diseases: Past, present, future. Phytother. Res. PTR 2010, 24, 1423–1432. [Google Scholar] [CrossRef]
  40. Hussein, R.M.; Sawy, D.M.; Kandeil, M.A.; Farghaly, H.S. Chlorogenic acid, quercetin, coenzyme Q10 and silymarin modulate Keap1-Nrf2/heme oxygenase-1 signaling in thioacetamide-induced acute liver toxicity. Life Sci. 2021, 277, 119460. [Google Scholar] [CrossRef]
  41. Lv, Q.; Hu, J.X.; Li, Y.J.; Xie, N.; Song, D.D.; Zhao, W.; Yan, Y.F.; Li, B.S.; Wang, P.Y.; Xie, S.Y. MiR-320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals. Cancer Biol. Ther. 2017, 18, 142–151. [Google Scholar] [CrossRef]
  42. Zhang, Q.; Yan, Y.F.; Lv, Q.; Li, Y.J.; Wang, R.R.; Sun, G.B.; Pan, L.; Hu, J.X.; Xie, N.; Zhang, C.; et al. miR-4293 upregulates lncRNA WFDC21P by suppressing mRNA-decapping enzyme 2 to promote lung carcinoma proliferation. Cell Death Dis. 2021, 12, 735. [Google Scholar] [CrossRef]
  43. Peng, J.; Wang, R.; Sun, W.; Huang, M.; Wang, R.; Li, Y.; Wang, P.; Sun, G.; Xie, S. Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer. Biomater. Sci. 2021, 9, 6528–6541. [Google Scholar] [CrossRef]
  44. Liu, Y.R.; Song, D.D.; Liang, D.M.; Li, Y.J.; Yan, Y.F.; Sun, H.F.; Zhang, M.L.; Hu, J.X.; Zhao, Y.L.; Liang, Y.; et al. Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession. Cell Death Discov. 2022, 8, 306. [Google Scholar] [CrossRef]
Molecules 28 07989 g001
Figure 1. The synthesis and structure of DMB. (A) The results of high-resolution mass spectrometry. (B) The structure of DMB.
Figure 1. The synthesis and structure of DMB. (A) The results of high-resolution mass spectrometry. (B) The structure of DMB.
Molecules 28 07989 g001
Molecules 28 07989 g002
Figure 2. The biochemical and histological changes in model rats. (A) The levels of ALT in sera significantly increased in CCl4-induced models; (B) the levels of AST in sera significantly increased in CCl4-induced models; (C) DBIL changed significantly in sera of model rats. (D) TBIL increased significantly in sera of model rats. (E) The changes in ALP in the sera of model rats. (F) The changes in LDH in the sera of model rats. (G) The histological changes in liver tissues of model rats. Data were abnormally distributed, and they are expressed as median (interquartile range), * p < 0.05, ** p < 0.01; Kruskal–Wallis H test. NS, no statistical difference.
Figure 2. The biochemical and histological changes in model rats. (A) The levels of ALT in sera significantly increased in CCl4-induced models; (B) the levels of AST in sera significantly increased in CCl4-induced models; (C) DBIL changed significantly in sera of model rats. (D) TBIL increased significantly in sera of model rats. (E) The changes in ALP in the sera of model rats. (F) The changes in LDH in the sera of model rats. (G) The histological changes in liver tissues of model rats. Data were abnormally distributed, and they are expressed as median (interquartile range), * p < 0.05, ** p < 0.01; Kruskal–Wallis H test. NS, no statistical difference.
Molecules 28 07989 g002
Molecules 28 07989 g003
Figure 3. DMB ameliorated the biochemical and histological changes in CCl4-induced models. (A) DMB significantly decreased ALT levels in sera of CCl4-induced models; (B) the levels of AST were reduced in DMB+CCl4-treated rats; (C) DBIL decreased in sera of DMB+CCl4-treated models. (D) TBIL decreased in sera of DMB+CCl4-treated models. (E) The changes in ALP in the sera of DMB+CCl4-treated rats. (F) The changes in LDH in the sera of DMB+CCl4-treated rats. (G) DMB ameliorated the histological changes in liver tissues of CCl4-induced models. Data were abnormally distributed, and they are expressed as median (interquartile range), * p < 0.05, ** p < 0.01 vs. CCl4 treatment; ##, ** p < 0.01 vs. negative control; Kruskal–Wallis H test. NS, no statistical difference.
Figure 3. DMB ameliorated the biochemical and histological changes in CCl4-induced models. (A) DMB significantly decreased ALT levels in sera of CCl4-induced models; (B) the levels of AST were reduced in DMB+CCl4-treated rats; (C) DBIL decreased in sera of DMB+CCl4-treated models. (D) TBIL decreased in sera of DMB+CCl4-treated models. (E) The changes in ALP in the sera of DMB+CCl4-treated rats. (F) The changes in LDH in the sera of DMB+CCl4-treated rats. (G) DMB ameliorated the histological changes in liver tissues of CCl4-induced models. Data were abnormally distributed, and they are expressed as median (interquartile range), * p < 0.05, ** p < 0.01 vs. CCl4 treatment; ##, ** p < 0.01 vs. negative control; Kruskal–Wallis H test. NS, no statistical difference.
Molecules 28 07989 g003
Molecules 28 07989 g004
Figure 4. DMB ameliorated the Nrf2-related factors in CCl4-induced liver injury. (A) The related protein Nrf2 of DMB was predicted; (B) DMB increased the content of GSH in the liver tissues of CCl4-treated rats. Data were abnormally distributed, and they are expressed as median (interquartile range), * p < 0.05, ** p < 0.01; Kruskal–Wallis H test. (C) DMB reduced the MDA levels in the liver tissues of CCl4-treated rats. Data are expressed as median (interquartile range), * p < 0.05, ** p < 0.01; Kruskal–Wallis H test. (D) Western blot analysis of Nrf2-related gene expression in the liver tissues; (E) Relative GCLC expression in the liver tissues. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (F) Relative Nrf2 expression in the liver tissues. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (G) Relative p53 expression in the liver tissues. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (H) DMB decreased the expression of Bax but increased Bcl2 expression in the liver tissues. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; NS, no statistical difference.
Figure 4. DMB ameliorated the Nrf2-related factors in CCl4-induced liver injury. (A) The related protein Nrf2 of DMB was predicted; (B) DMB increased the content of GSH in the liver tissues of CCl4-treated rats. Data were abnormally distributed, and they are expressed as median (interquartile range), * p < 0.05, ** p < 0.01; Kruskal–Wallis H test. (C) DMB reduced the MDA levels in the liver tissues of CCl4-treated rats. Data are expressed as median (interquartile range), * p < 0.05, ** p < 0.01; Kruskal–Wallis H test. (D) Western blot analysis of Nrf2-related gene expression in the liver tissues; (E) Relative GCLC expression in the liver tissues. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (F) Relative Nrf2 expression in the liver tissues. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (G) Relative p53 expression in the liver tissues. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (H) DMB decreased the expression of Bax but increased Bcl2 expression in the liver tissues. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; NS, no statistical difference.
Molecules 28 07989 g004
Molecules 28 07989 g005
Figure 5. DMB ameliorated the oxidative stress in vitro. (A,B) The IC50 values of HepG2 cells and MHCC-97H cells were determined using CCK-8 method. (C,D) After treatment of CCl4 or different concentrations of DMB for 24 h, the activities of HepG2 or MHCC-97H cells were analyzed using MTT, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (E) The content of MDA in HepG2 and MHCC-97H cells was estimated using a microplate reader. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (F) GSH content in HepG2 and MHCC-97H cells was determined. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (G,H) ROS content in HepG2 and MHCC-97H cells was analyzed after CCl4 or MB intervention for 24 h.
Figure 5. DMB ameliorated the oxidative stress in vitro. (A,B) The IC50 values of HepG2 cells and MHCC-97H cells were determined using CCK-8 method. (C,D) After treatment of CCl4 or different concentrations of DMB for 24 h, the activities of HepG2 or MHCC-97H cells were analyzed using MTT, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (E) The content of MDA in HepG2 and MHCC-97H cells was estimated using a microplate reader. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (F) GSH content in HepG2 and MHCC-97H cells was determined. Data are presented as the mean ± SD. * p < 0.05; ** p < 0.01; ANOVA. (G,H) ROS content in HepG2 and MHCC-97H cells was analyzed after CCl4 or MB intervention for 24 h.
Molecules 28 07989 g005
Molecules 28 07989 g006
Figure 6. DMB reversed CCl4-induced Nrf2 and GCLC expression. (A,B) Western blot detected the expression of Nrf2 and GCLC in HepG2 and MHCC-97H cells, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (C,D) Immunofluorescence analyses of the expression of Nrf2 in HepG2 and MHCC-97H cells, respectively. Bar = 50 μm.
Figure 6. DMB reversed CCl4-induced Nrf2 and GCLC expression. (A,B) Western blot detected the expression of Nrf2 and GCLC in HepG2 and MHCC-97H cells, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (C,D) Immunofluorescence analyses of the expression of Nrf2 in HepG2 and MHCC-97H cells, respectively. Bar = 50 μm.
Molecules 28 07989 g006
Molecules 28 07989 g007
Figure 7. DMB inhibited the apoptosis induced by CCl4. (A,B) The apoptotic rates of HepG2 and MHCC-97H cells were measured using flow cytometry and statistically counted, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (C,D) Western blot detected the expression of P53, Bax, and Bcl2 in HepG2 and MHCC-97H cells after CCl4 or MB interference, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA.
Figure 7. DMB inhibited the apoptosis induced by CCl4. (A,B) The apoptotic rates of HepG2 and MHCC-97H cells were measured using flow cytometry and statistically counted, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA. (C,D) Western blot detected the expression of P53, Bax, and Bcl2 in HepG2 and MHCC-97H cells after CCl4 or MB interference, respectively. Data are presented as the mean ± SD. ** p < 0.01; ANOVA.
Molecules 28 07989 g007
Molecules 28 07989 g008
Figure 8. Proposed model by which DMB reverses the roles of CCl4-induced liver injury. Blue arrows, the effects of CCl4 on gene expression, oxidative stress, cell apoptosis, and liver injury. Red arrows, the effects of DMB on ameliorating the roles of CCl4-induced liver injury.
Figure 8. Proposed model by which DMB reverses the roles of CCl4-induced liver injury. Blue arrows, the effects of CCl4 on gene expression, oxidative stress, cell apoptosis, and liver injury. Red arrows, the effects of DMB on ameliorating the roles of CCl4-induced liver injury.
Molecules 28 07989 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, R.; Shen, H.; Zhang, J.; Li, X.; Guo, Y.; Zhao, Z.; Wang, P.; Xie, N.; Li, Y.; Qu, G.; et al. Dimethyl Bisphenolate Ameliorates Carbon Tetrachloride-Induced Liver Injury by Regulating Oxidative Stress-Related Genes. Molecules 2023, 28, 7989. https://doi.org/10.3390/molecules28247989

AMA Style

Wang R, Shen H, Zhang J, Li X, Guo Y, Zhao Z, Wang P, Xie N, Li Y, Qu G, et al. Dimethyl Bisphenolate Ameliorates Carbon Tetrachloride-Induced Liver Injury by Regulating Oxidative Stress-Related Genes. Molecules. 2023; 28(24):7989. https://doi.org/10.3390/molecules28247989

Chicago/Turabian Style

Wang, Rong, Huanhuan Shen, Jiaxiang Zhang, Xiyan Li, Yang Guo, Zhenjun Zhao, Pingyu Wang, Ning Xie, Youjie Li, Guiwu Qu, and et al. 2023. "Dimethyl Bisphenolate Ameliorates Carbon Tetrachloride-Induced Liver Injury by Regulating Oxidative Stress-Related Genes" Molecules 28, no. 24: 7989. https://doi.org/10.3390/molecules28247989

Article Metrics

Back to TopTop